Working… Menu

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy (Bellini)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02755597
Recruitment Status : Suspended (Safety)
First Posted : April 29, 2016
Last Update Posted : April 27, 2021
Genentech, Inc.
Information provided by (Responsible Party):